News All News

A research team led by Christina Woo, professor of chemistry and chemical biology, in collaboration with a team of scientists at pharmaceutical company GSK and Scripps Research Institute, discovered a hidden binding pocket on the protein cereblon. The discovery of the allosteric cereblon binder could uncover a new area of cereblon biology to explore for cancer drugs.

Researchers in Andrew Kruse’s lab overcame a key obstacle in using the hormone relaxin as a therapy for heart disease. With support from Harvard’s Blavatnik Biomedical Accelerator, this discovery led to the launch of Tectonic Therapeutic, which is now testing its relaxin-based drug in clinical trials.

A new paper explores how stress can trigger hair loss and how our stress response can have long-term consequences for our scalps. The research may eventually yield insights into autoimmune diseases.

New research out of Harvard Medical School suggests that lithium deficiency may be a key driver of Alzheimer’s disease and a promising target for early diagnosis and treatment. Harvard’s Office of Technology Development has protected the innovations related to this research and is actively seeking industry partners for commercialization to advance these discoveries.